The Board of Directors of Sun Pharmaceutical Industries is scheduled to meet on January 31, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board will also consider the declaration of an interim dividend for the financial year 2025-26. If declared, the record date for determining eligible shareholders is set as February 05, 2026.
Upcoming Board Meeting
A meeting of the Board of Directors at Sun Pharmaceutical Industries is scheduled for January 31, 2026. The agenda includes reviewing and approving the Unaudited Standalone and Consolidated Financial Results for Q3 2026, specifically the quarter and nine-month period concluding on December 31, 2025.
Interim Dividend Consideration
The board will also deliberate on the potential declaration of an interim dividend for the financial year 2025-26. Should a dividend be declared, the company has fixed February 05, 2026, as the record date to identify shareholders eligible for the payout.
Trading Window Closure
The company’s trading window, which was previously closed starting January 01, 2026, will remain closed until February 02, 2026.
Source: BSE
